Michael S Lawrence
Overview
Explore the profile of Michael S Lawrence including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
42199
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mohamad-Ramshan R, Sakhtemani R, Butt Y, Lawrence M, Bhagwat A
NAR Mol Med
. 2025 Mar;
2(1):ugaf003.
PMID: 40083807
Introduction of uracils in specific regions within immunoglobulin genes by the activation-induced deaminase (AID) promotes mutations and double-strand breaks (DSBs). Although uracils are repaired through multiple DNA repair pathways, previous...
2.
Mishra A, Huang S, Dubash T, Burr R, Edd J, Wittner B, et al.
Nat Commun
. 2025 Jan;
16(1):32.
PMID: 39746954
Circulating Tumor Cells (CTCs) in blood encompass DNA, RNA, and protein biomarkers, but clinical utility is limited by their rarity. To enable tumor epitope-agnostic interrogation of large blood volumes, we...
3.
Bai B, Wise J, Vodak D, Nakken S, Sharma A, Blaker Y, et al.
Blood Cancer J
. 2024 Aug;
14(1):147.
PMID: 39191762
Follicular lymphoma (FL) is the most common indolent type of B-cell non-Hodgkin lymphoma. Advances in treatment have improved overall survival, but early relapse or transformation to aggressive disease is associated...
4.
Vijay V, Karisani N, Shi L, Hung Y, Vu P, Kattel P, et al.
bioRxiv
. 2024 Jul;
PMID: 39026794
Biliary tract cancers (BTCs) are a group of deadly malignancies encompassing intrahepatic and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. Here, we present the integrative analysis of 63 BTC cell...
5.
Zhang S, Yan C, Millar D, Yang Q, Heather J, Langenbucher A, et al.
Cancer Res
. 2024 May;
84(9):1534.
PMID: 38693893
No abstract available.
6.
Takahashi M, Chong H, Zhang S, Yang T, Lazarov M, Harry S, et al.
Cell
. 2024 Apr;
187(10):2536-2556.e30.
PMID: 38653237
Cysteine-focused chemical proteomic platforms have accelerated the clinical development of covalent inhibitors for a wide range of targets in cancer. However, how different oncogenic contexts influence cysteine targeting remains unknown....
7.
Mishra A, Huang S, Dubash T, Burr R, Edd J, Wittner B, et al.
bioRxiv
. 2024 Apr;
PMID: 38559183
Circulating Tumor Cells (CTCs), interrogated by sampling blood from patients with cancer, contain multiple analytes, including intact RNA, high molecular weight DNA, proteins, and metabolic markers. However, the clinical utility...
8.
Butt Y, Sakhtemani R, Mohamad-Ramshan R, Lawrence M, Bhagwat A
Nat Commun
. 2024 Mar;
15(1):2369.
PMID: 38499553
The APOBEC3 enzymes convert cytosines in single-stranded DNA to uracils to protect against viruses and retrotransposons but can contribute to mutations that diversify tumors. To understand the mechanism of mutagenesis,...
9.
Sanchez A, Ortega P, Sakhtemani R, Manjunath L, Oh S, Bournique E, et al.
Nat Commun
. 2024 Mar;
15(1):2370.
PMID: 38499542
Antiviral DNA cytosine deaminases APOBEC3A and APOBEC3B are major sources of mutations in cancer by catalyzing cytosine-to-uracil deamination. APOBEC3A preferentially targets single-stranded DNAs, with a noted affinity for DNA regions...
10.
Pal Choudhuri S, Girard L, Lim J, Wise J, Freitas B, Yang D, et al.
Cancer Discov
. 2024 Feb;
14(5):804-827.
PMID: 38386926
Significance: SCLC is initially chemosensitive, but acquired cross-resistance renders this disease refractory to further treatment and ultimately fatal. The genomic drivers of this transformation are unknown. We use a population...